Quantum BioPharma Ltd. (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, highlighting improved liquidity, reduced operating expenses, and progress in its clinical development program. Cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets. Shareholders’ equity increased 91% to $9.77 million, while working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million.
Following quarter-end, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Quantum also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months.
The financial improvements and clinical progress are detailed in the full press release available at https://ibn.fm/GJ1ER. For investors seeking ongoing updates on Quantum BioPharma, the company’s newsroom is accessible through https://ibn.fm/QNTM.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, offering access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The improved financial position and the advancement of the Lucid-MS Phase 2 trial could have significant implications for Quantum BioPharma and the treatment of progressive multiple sclerosis. With sufficient cash and digital assets to support operations over the next 12 months, the company is well-positioned to continue its clinical development efforts. The reduction in operating expenses and net loss further strengthens its financial stability, potentially attracting investor confidence. For the broader industry, the progress of Lucid-MS, a compound shown to prevent and reverse myelin degradation in preclinical models, offers hope for a novel therapeutic approach to multiple sclerosis, a condition with limited treatment options. The agreement with Thermo Fisher Scientific’s clinical research business underscores the importance of strategic partnerships in advancing clinical trials. As Quantum BioPharma moves forward, stakeholders will be watching closely for trial results and further developments in its pipeline.
